Pfizer Cleared in Multistate Antitrust Suit Over Generic Price-Fixing
PFE is trading near its 52-week low of $23.11 (4.3% above the low) on elevated volume (2.0× avg).
Summary
A judge dismissed Pfizer as a defendant in a multistate antitrust suit concerning alleged price-fixing of 80 generic drugs. This removes a significant legal and financial overhang, de-risking the company from potential penalties and reputational damage. The company also declared a routine $0.43 cash dividend for Q3 2026. This positive legal development adds to a series of recent favorable news for Pfizer, including strong clinical trial results and strategic acquisitions.
At the time of this announcement, PFE was trading at $24.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $137B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.